Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADVISE: Adaptive Biomarker Trial in Advanced Solid Tumors
NCT03335540Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- May 2018
- Primary completion
- Mar 2021
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label trial of relatlimab, cabiralizumab, ipilimumab and linrodostat in solid tumor (advanced stage) (5 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Number of participants with qualified tumor biopsy specimen at baseline up to 28 days. Started May 2018; status: completed.
02
Drugs
relatlimabcabiralizumabipilimumablinrodostat
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT03335540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03335540.